Clinical Trial of HG146 Administered to Subjects With Advanced Solid Tumors or Lymphoma
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase I, open-label, repeat-dose, non-randomized, multicenter study to evaluate the
safety, tolerability, and preliminary clinical activity and establish a recommended dose of
HG146 administered orally (PO) alone (Part 1) or co-administered (Part 2) with PD-（L）1
inhibitor in subjects with refractory/relapsed solid tumors or Lymphoma. Part 1 consists of a
dose escalation phae,Part2 consists of a dose escalation phase and a cohort expansion phase.
In Part 1, escalating doses of HG146 will be evaluated as guided by the "3+3" approach. In
Part 2A, escalating doses of HG146 in combination with PD-(L)1 inhibitor will be evaluated as
guided by the "3+3" approach. In Part 2B, subjects will receive a single dose level of HG146
as identified based on data from Part 2, in combination with PD-(L)1 inhibitor . A total of
approximately 96 subjects will be enrolled in this study, approximately 36 for dose
escalation cohorts, and approximately 60 in the expansion cohorts.